Loading clinical trials...
Loading clinical trials...
An Open-Label, Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis
The purpose of the study is 1) to study the safety and tolerability of escalating doses of myelin peptide reactive T cells in MS patients and 2) to study the clinical effectiveness of T Cell Vaccine ion the clinical course of MS.
The principle of TCV is similar to that of traditional microbial vaccination where attenuated infectious agents are used to stimulate protective immune responses. Because pathogentic autoreactive T cells are viewed as pathogens in T cell-mediated autoimmune diseases, they can be used, as a vaccine to prevent and treat the diseases in which they are able to induce.
Age
18 - 65 years
Sex
ALL
Healthy Volunteers
No
Bellaire Neurology
Bellaire, Texas, United States
Baylor College of Medicine
Houston, Texas, United States
Start Date
July 1, 2002
Primary Completion Date
June 1, 2007
Completion Date
December 1, 2008
Last Updated
January 11, 2017
16
ACTUAL participants
Tovaxin Autologous T Cell Vaccine
BIOLOGICAL
Lead Sponsor
Opexa Therapeutics, Inc.
NCT06276634
NCT05359653
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions